Day: February 28, 2020

AFARAK GROUP OYJ: TILINPÄÄTÖSTIEDOTE 2019

Written by Customer Service on February 28, 2020. Posted in Earnings Releases And Operating Results.

12:30 Lontoo, 13:30 Helsinki, 28.2.2020 – Afarak Group Oyj (”Afarak” tai ”Yhtiö) (LSE: AFRK, NASDAQ: AFAGR)AFARAK GROUP OYJ:N TILINPÄÄTÖSTIEDOTE 2019VUODEN 2019 NELJÄNNEN NELJÄNNEKSEN YHTEENVETOLiikevaihto laski 39,2 prosenttia 28,6 miljoonaan euroon (Q4/2018 47,0) alhaisempien myyntivolyymien ja alhaisempien myyntihintojen takia;Jalostettujen tuotteiden myynti laski 34,5 prosenttia 16 914 tonniin (Q4/2018 25 833 tonnia);Louhittu tonnimäärä laski 28,8 prosenttia 73 021 tonniin (Q4/2018: 102 562) Etelä-Afrikan kaivoksilla väliaikaisesti keskeytetyn kaivostoiminnan takia;Konsernin käyttökate laski -6,3 miljoonaan euroon (Q4/2018: 1,0) ja käyttökateprosentti oli -22,1 (Q4/2018: 2,1);Liikevoitto oli -15,4 miljoonaa euroa (Q4/2018: -7,0) ja liikevoittoprosentti -53,8 (Q4/2018: -14,9);Mogalen liiketoimintoihin liittyvistä muista pitkäaikaisista...

Mersana Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Updates

Written by Customer Service on February 28, 2020. Posted in Public Companies.

XMT-1536 Phase 1 dose escalation data update selected for late-breaker oral presentation at upcoming Society of Gynecologic Oncology (SGO) 2020 Annual Meeting on Women’s CancerXMT-1536 interim Phase 1 dose expansion data to be presented in 2Q 2020 with more mature data expected in 2H 2020Company to present preclinical data on ADCs created with the Dolasynthen and Immunosynthen platforms at the American Association for Cancer Research (AACR) Annual MeetingCAMBRIDGE, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today reported financial results and provided a business update for the fourth quarter and full year ended...

Acura Pharmaceuticals Announces Third Quarter 2019 Financial Results

Written by Customer Service on February 28, 2020. Posted in Public Companies.

PALATINE, Ill., Feb. 28, 2020 (GLOBE NEWSWIRE) — Acura Pharmaceuticals, Inc. (OTC: ACUR), a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse, announced today financial results for the three and nine months ended September 30, 2019.The Company reported an operating income of $0.3 million for the third quarter 2019 compared to an operating loss of $1.0 million for the same period in 2018. For the nine months ended September 30, 2019, the Company reported an operating loss of $1.0 million compared to an operating loss of $3.7 million for the same period in 2018.The Company reported net income of $0.2 million or $0.00 per diluted share for the third quarter 2019 compared to a net...

Fennec Pharmaceuticals Receives European Medicines Agency Validation for Marketing Authorization Application for Sodium Thiosulfate

Written by Customer Service on February 28, 2020. Posted in Public Companies.

RESEARCH TRIANGLE PARK, N.C., Feb. 28, 2020 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the company’s Marketing Authorization Application (MAA) for its investigational drug, sodium thiosulfate (unique formulation) for infusion (tradename to be determined in EU), has passed validation and is now under evaluation by the European Medicines Agency (EMA). The MAA for Pediatric Use Marketing Authorization (PUMA) was filed in early February 2020 for the prevention of ototoxicity induced by cisplatin chemotherapy in patients one month to < 18 years of age with localized, non-metastatic, solid tumors. “The EMA validation of our marketing application represents another step forward in our efforts to address, if authorized, the critical unmet medical...

Regarding recommendation of the working group set up by the Ministry of Finance and the proposal to approve the actions authorizing to prepare for the initial public offering of shares of UAB Ignitis Grupė

Written by Customer Service on February 28, 2020. Posted in Public Companies.

UAB Ignitis Grupė, (hereinafter – the Company) identification code 301844044, registered office placed at Žvejų str. 14, Vilnius, Republic of Lithuania. The total nominal value of issued bonds 600 000 000 EUR; ISIN codes XS1646530565; XS1853999313.The Company informs that on 28th February 2020 it received a letter (hereinafter referred to as the “Letter”) from the Ministry of Finance of the Republic of Lithuania, the authority implementing the rights of the sole shareholder of the Company (hereinafter referred to as the “Ministry of Finance”), notifying that on 28th February 2020 the working Group, which assessed the alternatives of long-term financing of the Company (hereinafter the “Working Group”), submitted its recommendation (hereinafter the “Recommendation”).It is stated in the Recommendation that, having considered all alternatives...

Dėl Finansų ministerijos inicijuotos darbo grupės rekomendacijų ir siūlymo pritarti UAB „Ignitis grupė“ pirminio viešo akcijų siūlymo inicijavimo veiksmams

Written by Customer Service on February 28, 2020. Posted in Public Companies.

UAB „Ignitis grupė“ (toliau – Bendrovė), juridinio asmens kodas: 301844044, registruotos buveinės adresas: Žvejų g. 14, Vilnius. Bendra UAB „Ignitis grupė“ išleistų obligacijų nominali vertė 600 000 000 EUR; ISIN kodai: XS1646530565; XS1853999313.Bendrovė informuoja, kad 2020 m. vasario 28 d. gavo jos vienintelio akcininko teises įgyvendinančios Lietuvos Respublikos finansų ministerijos (toliau – Finansų ministerija) raštą (toliau – Raštas), kuriuo informuojama apie tai, kad Bendrovės ilgalaikio finansavimo alternatyvas vertinusi darbo grupė (toliau – Darbo grupė) 2020 m. vasario 28 d. pateikė savo rekomendacijas (toliau – Rekomendacijos).Rekomendacijose nurodoma, kad, įvertinusi visas svarstytas Bendrovės ilgalaikio finansavimo alternatyvas, Darbo grupė priėjo prie išvados, jog iš galimų akcinio kapitalo pritraukimo būdų efektyviausias...

Grace Increases Share Repurchase Authorization to $250 Million

Written by Customer Service on February 28, 2020. Posted in Public Companies.

COLUMBIA, Md., Feb. 28, 2020 (GLOBE NEWSWIRE) — W. R. Grace & Co. (NYSE:GRA) today announced that its Board of Directors increased its share repurchase authorization to $250 million, including approximately $83 million remaining under its previously-announced program. In the first quarter, Grace has repurchased more than $25 million of its common stock. Since February 2014, the company has repurchased approximately $1.2 billion of its common stock.“We are confident in our long-term growth drivers and the payback on the commercial excellence and operating excellence investments we are making,” said Hudson La Force, Grace’s President and Chief Executive Officer. “This authorization demonstrates our continued commitment to increasing long-term shareholder value. Our strong balance sheet and cash flow provide the flexibility to...

Number of shares in Klövern as of 28 February 2020

Written by Customer Service on February 28, 2020. Posted in Public Companies.

After conversion of 2,592,545 Class A ordinary shares to Class B ordinary shares during the month of February the total number of shares in Klövern as of 28 February 2020 amounts to 932,437,980, of which 69,358,703 constitute Class A ordinary shares, 846,635,277 constitute Class B ordinary shares and 16,444,000 constitute preference shares. Each Class A ordinary share entitles to one vote whereas each Class B ordinary share, as well as each preference share, entitles to one-tenth of a vote. The total number of votes in the company after the conversion amounts to 155,666,630.7.Klövern AB (publ)For additional information, please contact:Rutger Arnhult, CEO, +46 (0)70-458 24 70, rutger.arnhult@klovern.seLars Norrby, IR, +46 (0)76-777 38 00, lars.norrby@klovern.seKlövern is a real estate company committed to working closely with customers...

Bayport Management Limited Unaudited Financial Statement 31 December 2019

Written by Customer Service on February 28, 2020. Posted in Public Companies.

Bayport Management LimitedUnaudited Condensed Consolidated Financial Statementsfor the twelfe months ended 31 December 2019AttachmentsBML QFR December 2019 – Quarterly Report – Q4BML QFR December 2019 – Quarterly Report – Q4

Itaú Corpbanca Announces Fourth Quarter 2019 Management Discussion & Analysis Report

Written by Customer Service on February 28, 2020. Posted in Public Companies.

SANTIAGO, Chile, Feb. 28, 2020 (GLOBE NEWSWIRE) — ITAÚ CORPBANCA (NYSE: ITCB; SSE: ITAUCORP) announced today its Management Discussion & Analysis Report (“MD&A Report”) for the fourth quarter ended December 31, 2019.The financial information included in the MD&A Report is based on our managerial model that we adjust for non-recurring events and for additional reclassifications of P&L lines in order to provide a better understanding of our performance.For the full MD&A Report, please refer to the following link: https://wcc.on24.com/webcast/report?e=2152667&k=C19F454E4FB558825A735D9A77C36118On Monday, March 2, 2020, at 11:00 A.M. Santiago time (09:00 AM ET), the Company’s management team will host a conference call to discuss the financial results. The call will be hosted by Gabriel Moura, Itaú Corpbanca’s...

Day: February 28, 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals